Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Davita Healthcare Partners Inc (DVA)

Davita Healthcare Partners Inc (DVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Hedge Funds Are Shorting This Classic Warren Buffett Stock. Should You Sell Shares Now?

Healthcare provider stocks are falling out of favor as higher operating expenses and renewed debate over patient subsidies pressure earnings across the sector. Hedge funds have responded by turning aggressive sellers, building short positions in U.S. healthcare providers, especially dialysis and hospital operators, where shorts now outnumber long positions by roughly eight to one.

DaVita (DVA) sits at the center of that bearish trade. Short interest in the dialysis operator climbed to about 11.6% of its float by year-end, up roughly 12% in just one month, putting it among the most shorted names in the S&P 500 ($SPX).

Fundamentals

See More
  • Market Capitalization, $K 7,394,643
  • Shares Outstanding, K 70,600
  • Annual Sales, $ 12,816 M
  • Annual Income, $ 936,340 K
  • EBIT $ 2,751 M
  • EBITDA $ 3,475 M
  • 60-Month Beta 0.99
  • Price/Sales 0.62
  • Price/Cash Flow 5.53
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 40.67% (+1.37%)
  • Historical Volatility 23.08%
  • IV Percentile 73%
  • IV Rank 51.49%
  • IV High 57.57% on 04/08/25
  • IV Low 22.74% on 02/18/25
  • Expected Move (DTE 33) 9.35 (8.93%)
  • Put/Call Vol Ratio 20.83
  • Today's Volume 917
  • Volume Avg (30-Day) 2,615
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 29,933
  • Open Int (30-Day) 24,023
  • Expected Range 95.39 to 114.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 3.24
  • Number of Estimates 2
  • High Estimate 3.29
  • Low Estimate 3.18
  • Prior Year 2.24
  • Growth Rate Est. (year over year) +44.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.00 +3.70%
on 01/14/26
120.08 -12.77%
on 12/17/25
-13.20 (-11.19%)
since 12/16/25
3-Month
101.00 +3.70%
on 01/14/26
130.82 -19.94%
on 10/29/25
-20.51 (-16.38%)
since 10/16/25
52-Week
101.00 +3.70%
on 01/14/26
179.60 -41.68%
on 01/31/25
-60.11 (-36.46%)
since 01/16/25

Most Recent Stories

More News
Hedge Funds Are Shorting This Classic Warren Buffett Stock. Should You Sell Shares Now?

Hedge funds are betting against DaVita, but low valuations and steady cash flow suggest this Buffett stock may be bruised, not broken.

$SPX : 6,940.01 (-0.06%)
BRK.A : 740,750.00 (+0.28%)
BRK.B : 493.29 (+0.14%)
DVA : 104.74 (-1.04%)
Here's What to Expect From DaVita's Next Earnings Report

DaVita is set to announce its fourth-quarter results soon, with analysts forecasting a double-digit increase in the company’s bottom-line figure.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
DVA : 104.74 (-1.04%)
Behind Berkshire’s Curtain: Is Greg Abel Preparing to Cut Davita Loose?

Davita hit its 23rd new 52-week low on Tuesday. Its stock is now within a few dollars of trading in double digits. That’s not a good thing, given that its share price was nearly $180 a year ago.

KO : 70.44 (-0.06%)
BRK.B : 493.29 (+0.14%)
AXP : 364.79 (+2.08%)
DVA : 104.74 (-1.04%)
UNH : 331.02 (-2.34%)
1 Value Stock on Our Buy List and 2 We Brush Off

1 Value Stock on Our Buy List and 2 We Brush Off

BWIN : 26.64 (+1.80%)
PAHC : 41.07 (+2.52%)
DVA : 104.74 (-1.04%)
3 Profitable Stocks That Concern Us

3 Profitable Stocks That Concern Us

HRL : 24.22 (-2.02%)
LMAT : 88.27 (+2.05%)
DVA : 104.74 (-1.04%)
Is DaVita Stock Underperforming the Dow?

As DaVita has underperformed relative to the Dow over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

HCA : 469.29 (-3.00%)
$DOWI : 49,359.33 (-0.17%)
DVA : 104.74 (-1.04%)
DaVita Names New Leaders to Accelerate Care Transformation

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach

DVA : 104.74 (-1.04%)
3 Cash-Producing Stocks We Keep Off Our Radar

3 Cash-Producing Stocks We Keep Off Our Radar

MTRX : 13.71 (+1.11%)
M : 21.74 (+0.79%)
DVA : 104.74 (-1.04%)
2 Small-Cap Stocks to Keep an Eye On and 1 That Underwhelm

2 Small-Cap Stocks to Keep an Eye On and 1 That Underwhelm

LMB : 84.49 (-2.52%)
NIC : 131.46 (-1.22%)
DVA : 104.74 (-1.04%)
3 of My Favorite Index Funds for 2026

If you want accessible, useful, and downright cheap funds to anchor your portfolio, these three index funds can do it better than most.

NVDA : 186.23 (-0.44%)
VHYAX : 44.89 (+0.11%)
JPM : 312.47 (+1.04%)
FUMBX : 10.34 (-0.10%)
JNJ : 218.66 (-0.41%)
XOM : 129.89 (+0.59%)
VYM : 148.87 (+0.11%)
FXAIX : 241.14 (-0.06%)
DVA : 104.74 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals...

See More

Key Turning Points

3rd Resistance Point 108.09
2nd Resistance Point 107.21
1st Resistance Point 105.97
Last Price 104.74
1st Support Level 103.85
2nd Support Level 102.97
3rd Support Level 101.73

See More

52-Week High 179.60
Fibonacci 61.8% 149.57
Fibonacci 50% 140.30
Fibonacci 38.2% 131.03
Last Price 104.74
52-Week Low 101.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar